Science
New Phase 1/2 Data for Advanced RAS-Driven Non-Small Cell Lung Cancer – Revolution Medicines
Revolution Medicines/Struck

New Phase 1/2 Data for Advanced RAS-Driven Non-Small Cell Lung Cancer – Revolution Medicines

Revolution Medicines shared on LinkedIn:

“We’re excited to share that Phase 1/2 data for our RAS(ON) multi-selective inhibitor being investigated in patients with previously treated advanced RAS mutant non-small cell lung cancer have been published in NEJM Group.

Read the full details in our press release.”

New Phase 1/2 Data for Advanced RAS-Driven Non-Small Cell Lung Cancer - Revolution Medicines

You can also read: Daraxonrasib Opens a Broader RAS-Targeting Strategy in Previously Treated NSCLC

Revolution Medicines

 

cancer Lung cancer NEJM non small cell lung cancer OncoDaily Oncology RAS mutant cancer RevMed Revolution Medicines